





UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/955,248 09/17/2001		09/17/2001	Leo Martis	DI-4641 CONT	8992
29200	7590	01/14/2003			
		CARE CORPORA	EXAMINER		
RENAL DI' 1 BAXTER		ΛY	KEYS, ROSALYND ANN		
DF3-3E DEERFIEL	D, IL 600	15		. ART UNIT	PAPER NUMBER
	•			1621	10
				DATE MAILED: 01/14/2003	12

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)	_				
_							
Offic Action Summary	09/955,248	MARTIS ET AL.					
omo Addon dammary	Examiner	Art Unit					
The MAILING DATE of this communication app	Rosalynd Keys	1621					
Period for Reply	ears on the cover sheet v	nui die correspondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	B6(a). In no event, however, may a within the statutory minimum of th will apply and will expire SIX (6) MC cause the application to become A	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on <u>28 C</u>	October 2002 .						
2a)⊠ This action is FINAL . 2b)□ Thi	s action is non-final.						
 Since this application is in condition for allowa closed in accordance with the practice under E Disposition of Claims 							
4) Claim(s) 1-16 is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	vn from consideration.						
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-16</u> is/are rejected.	☑ Claim(s) <u>1-16</u> is/are rejected.						
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	election requirement.						
Application Papers							
9) The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accep	-						
Applicant may not request that any objection to the 11) The proposed drawing correction filed on	= ' '	• •					
If approved, corrected drawings are required in rep		uisapproved by the Examiner.					
12) The oath or declaration is objected to by the Exa	•						
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign	priority under 35 H.S.C.	8 119(a)-(d) or (f)					
a) ☐ All b) ☐ Some * c) ☐ None of:	phonty under do 0.0.0.	3 110(d) (d) 61 (l).					
1.☐ Certified copies of the priority documents	s have been received.						
<u> </u>							
Copies of the certified copies of the priori application from the International Bur See the attached detailed Office action for a list of the certified copies of the priori application from the International Bur	ity documents have beer eau (PCT Rule 17.2(a)).	received in this National Stage					
14) Acknowledgment is made of a claim for domestic	priority under 35 U.S.C	§ 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language products 15)☐ Acknowledgment is made of a claim for domestic							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 11	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)					

Application/Control Number: 09/955,248 Page 2

Art Unit: 1621

DETAILED ACTION

Status of Claims

1. Claims 1-16 are pending.

Claims 1-16 are rejected.

Information Disclosure Statement

2. The information disclosure statement filed October 28, 2002 has been considered.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 4. Claims 1, 2, and 4-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Schambye et al. (Peritoneal Dialysis International, Vol. 13, Supplemental 2, October 1992, pp. S116-S118) in view of Zander (US Patent No. 5,296,242), for the reasons given in the previous office action, Paper No. 9.
- 5. Claims 1, 2, and 4-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Veech (US 4,663,166) in view of Zander (US Patent No. 5,296,242), for the reasons given in the previous office action, Paper No. 9.

Application/Control Number: 09/955,248 Page 3

Art Unit: 1621

Claim Rejections - 35 USC § 103

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 8. Claims 1-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schambye et al. (Peritoneal Dialysis International, Vol. 13, Supplemental 2, October 1992, pp. S116-S118) in view of Zander (US Patent No. 5,296,242), for the reasons given in the previous office action, Paper No. 9.
- 9. Claims 1-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Veech et al. (US 4,663,166) in view of Zander (U.S. Patent No. 5,296,242), for the reasons given in the previous office action, Paper No. 9.
- 10. Claims 1-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Veech (US 6,020,007) in view of Zander (US 5,296,242), for the reasons given in the previous office action, Paper No. 9.

Response to Arguments

Rejection of claims 1, 2, and 4-8 under 35 U.S.C. 102(b) as being anticipated by Schambye et al. (Peritoneal Dialysis International, Vol. 13, Supplemental 2, October

1992, pp. S116-S118) in view of Zander (US Patent No. 5,296,242) and claims 1, 2, and 4-8 under 35 U.S.C. 102(b) as being anticipated by Veech (US 4,663,166) in view of Zander (US Patent No. 5,296,242)

11. Applicant's arguments filed October 28, 2002 have been fully considered but they are not persuasive.

Applicants argue that as a matter of law, anticipation requires the disclosure in a single (emphasis added) prior art reference of each element of the claim under consideration. This argument is not persuasive because normally, only one reference should be used in making a rejection under 35 U.S.C. 102. However, a 35 U.S.C. 102 rejection over multiple references has been held to be proper when the extra references are cited to:

- (A) Prove the primary reference contains an "enabled disclosure;"
- (B) Explain the meaning of a term used in the primary reference; or
- (C) Show that a characteristic not disclosed in the reference is inherent.

 In the instant case multiple references are being used to show that a characteristic not disclosed in the reference is inherent. In particular, Zander is combined with Schambye et al. to show that the claimed carbon dioxide partial pressure is inherently taught by Schambye et al.

The Applicants further argue that even if the anticipation rejections are not considered improper as a matter of law, applicants respectfully submit that the cited references fail to disclose a number of features of the claimed invention. The Examiner

Application/Control Number: 09/955,248

Art Unit: 1621

disagrees. The cited references do teach each and every element of the claimed invention, which is pointed out in the previous office action, Paper No. 9.

For the above reasons, the rejection of claims 1, 2, and 4-8 under 35 U.S.C. 102(b) as being anticipated by Schambye et al. in view of and the rejection of claims 1, 2, and 4-8 under 35 U.S.C. 102(b) as being anticipated by Veech in view of Zander are maintained.

Rejection of claims 1- under 35 U.S.C. 103(a) as being unpatentable over Schambye et al. (Peritoneal Dialysis International, Vol. 13, Supplemental 2, October 1992, pp. S116-S118) in view of Zander (US Patent No. 5,296,242; Rejection of claims 1-16 under 35 U.S.C. 103(a) as being unpatentable over Veech et al. (US 4,663,166) in view of Zander (U.S. Patent No. 5,296,242; and rejection of claims 1-16 under 35 U.S.C. 103(a) as being unpatentable over Veech (US 6,020,007) in view of Zander (US 5,296,242

The Applicants argue that the primary references are clearly deficient with respect to the claimed invention. The Examiner disagrees for reasons given in the previous office actions.

The bulk of the Applicants' arguments are directed to the Zander reference.

The applicants argue that while Zander does teach a dialysis solution with a carbon dioxide partial pressure of about 40 mmHg, a person skilled in the art of peritoneal dialysis would readily recognize that the solutions proposed by Zander would not be effective in maintaining the acid-base balance of dialysis patients. This argument is not persuasive because 1) it is not the solution of Zander that the instant claims are found

Art Unit: 1621

to be unpatentable, but the solution that results as a combination of the primary references with the carbon dioxide partial pressure disclosed by Zander (see previous office action, Paper No. 9); and 2) Zander teaches that by using carbon dioxide partial pressures that correspond to physiological blood plasma (40 mm Hg) one can prevent alkalosis or acidosis from occurring (see column 2, lines 35-54).

With regard to the Applicants arguments that the preferred weak acid of Zander is clearly acetic acid/acetate, the Examiner wishes to remind the applicants that it is well established that consideration of a reference is not limited to the preferred embodiments or working examples, but extends to the entire disclosure for what it fairly teaches to a person of ordinary skill in the art. *In re Boer*, 355 F.2d 961, 148 USPQ 507 (CCPA 1966); In re Lamberti, 545 F.2d 747, 750, 192 USPQ 279, 280 (CCPA 1976); In re Fracalossi, 681 F.2d 792, 794, 215 USPQ 569, 570 (CCPA 1982); In re Kaslow, 707 F.2d 1366, 1374, 217 USPQ 1089, 1095 (Fed. Cir. 1983). In the instant case, Zander clearly suggests the use of other weak acids, including the claimed weak acids, which are also taught by the primary references.

Any further arguments with regard to Zander teaching the use of acetic acid/acetate will not be addressed by the Examiner because the rejection is not based on the use of acetic acid/acetate as taught by Zander, but on the combination of Zander with the primary references, as mentioned above. It is this combination of references that the applicants' invention has failed to patentably distinguish over. Further, it has been held that one cannot show non-obviousness by attacking references individually

Application/Control Number: 09/955,248

Art Unit: 1621

where, as here, the rejections are based on combinations of references. *In re Keller*, 208 USPQ 871 (CCPA 1981).

In response to Applicants' arguments that the Examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the invention was made, and does not include knowledge gleaned only from the applicants' disclosure, such a reconstruction is proper. *In re McLaughlin*, 443 F.2d 1392; 170 USPQ 209 (CCPA 1971). In the instant case, all elements of the claimed invention are disclosed by the cited references. There is no element or part of Applicants' claimed invention, which is not suggested or specifically disclosed. The motivation to combine the teaching of the references is found in column 2, lines 35-54 of Zander.

The Applicants' argue that the Examiner's conclusion of obviousness is based upon an "obvious to try" rationale. The Examiner disagrees because the cited references disclose the use of each of the claimed elements in a peritoneal dialysis solution as well as the reason or motivation for using the claimed amounts of each of the elements.

The Applicants' argue that Zander teaches away from its combination with the cited primary references. The Examiner disagrees. In column 3, lines 62-68 Zander teaches that the inventive solutions contain the immediate buffer bicarbonate in physiological concentration, together with the long-term buffer metabolized anion in the

desired concentration. Preferred metabolizable acids useable in the aqueous solutions according to the invention are pyruvic, lactic, oxalic, fumaric, acetic, malic, maleic, malonic and succinic acids. The solution disclosed in Schambye et al. contain bicarbonate and lactate. The solutions disclosed in Veech '166 and Veech '007 contain bicarbonate with pyruvate and/or lactate. Thus, the possible dialysis solutions disclosed by Zander correspond to the dialysis solutions, which are disclosed by the primary references. What is lacking in the primary references is a specific teaching to use physiological carbon dioxide partial pressures, i.e., a carbon dioxide partial pressure of 40 mmHg. Zander teaches using a physiological carbon dioxide partial pressure. The reason to use such pressure has been given above, as well as in the previous office action, Paper No. 9.

The Examiner believes a prima facie case of obviousness has been shown.

Thus, for the above reasons the rejections under 35 USC 103(a) are maintained.

Conclusion

12. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

Application/Control Number: 09/955,248

Art Unit: 1621

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the mailing date of this final action.

13. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Rosalynd Keys whose telephone number is 703-308-

4633. The examiner can normally be reached on M and F 3:00-8:00 pm and T-R 5:30-

10:30 am.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Johann Richter can be reached on 703-308-4532. The fax phone numbers

for the organization where this application or proceeding is assigned are 703-872-9306

for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 703-308-

1235.

January 10, 2003

Page 9

Primary Examiner Art Unit 1621